Browse > Article
http://dx.doi.org/10.4014/jmb.0910.10018

Evaluation of Inhibitory Effects of Thiobarbituric Acid Derivatives Targeting HCV NS5B Polymerase  

Lee, Jong-Ho (Department of Bioscience and Biotechnology, Hankuk University of Foreign Studies)
Lee, Sang-Yoon (Department of Bioscience and Biotechnology, Hankuk University of Foreign Studies)
Park, Mi-Young (Department of Bioscience and Biotechnology, Hankuk University of Foreign Studies)
Ha, Hyun-Joon (Department of Chemistry, Hankuk University of Foreign Studies)
Myung, Hee-Joon (Department of Bioscience and Biotechnology, Hankuk University of Foreign Studies)
Publication Information
Journal of Microbiology and Biotechnology / v.20, no.3, 2010 , pp. 510-512 More about this Journal
Abstract
A series of thiobarbituric acid derivatives were constructed and evaluated for inhibitory activity on hepatitis C virus NS5B polymerase. In biochemical assays using purified viral polymerase and RNA template, the $IC_{50}$ value was improved to 0.41 ${\mu}M$ from the original compound's 1.7 ${\mu}M$ value. In HCV sub genomic replicon assay, the $EC_{50}$ value was improved to 3.7 ${\mu}M$ from the original compound's 12.3 ${\mu}M$ value. $CC_{50}$ was higher than 77 ${\mu}M$ for all compounds tested, suggesting that they are useful candidates for anti-HCV therapy.
Keywords
Hepatitis C virus; NS5B polymerase; inhibitor; thiobarbituric acid;
Citations & Related Records
Times Cited By KSCI : 1  (Citation Analysis)
Times Cited By Web Of Science : 0  (Related Records In Web of Science)
연도 인용수 순위
1 Beaulieu, P. L. 2007. Non-nucleoside inhibitors of the HCV NS5B polymerase: Progress in the discovery and development of novel agents for the treatment of HCV infections. Curr. Opin. Investig. Drugs 8: 614-634.
2 Ha, H. J., S. M. Han, S. W. Ko, K. E. Cha, J. H. Lee, and H. Myung. 2007. Thiobarbituric acid derivatives for anti-HCV agents targeting NS5B RNA polymerase. Bull. Korean Chem. Soc. 28: 1917-1918.   DOI
3 Bustin, S. A. 2000. Absolute quantification of mRNA using real-time reverse transcription polymerase chain reaction assays. J. Mol. Endocrinol. 25: 169-193.   DOI   ScienceOn
4 Ni, Z. J. and A. S. Wagman. 2004. Progress and development of small molecule HCV antivirals. Curr. Opin. Drug Discov. Devel. 7: 446-459.
5 Wasley, A. and M. J. Alter. 2000. Epidemiology of hepatitis C: Geographic differences and temporal trends. Semin. Liver Dis. 20: 1-16.
6 Lee, S., J. Lee, Y. Kee, M. Park, and H. Myung. 2005. Partial reconstitution of hepatitis C virus RNA replication by heterologous expression of NS5B polymerase and template RNA in bacterial cell. Virus Res. 114: 158-163   DOI   ScienceOn
7 Lohmann, V., F. Korner, J. Koch, U. Herian, L. Theilmann, and R. Bartenschlager. 1999. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 285: 110-113.   DOI   ScienceOn
8 Kwong, A. D., L. McNair, I. Jacobson, and S. George. 2008. Recent progress in the development of selected hepatitis C virus NS3.4A protease and NS5B polymerase inhibitors. Curr. Opin. Pharmacol. 8: 522-531.   DOI   ScienceOn
9 Yamashita, T., S. Kaneko, Y. Shirota, W. Qin, T. Nomura, K. Kobayashi, and S. Murakami. 1998. RNA-dependent RNA polymerase activity of the soluble recombinant hepatitis C virus NS5B protein truncated at the C-terminal region. J. Biol. Chem. 273: 15479-15486.   DOI
10 Choo, Q. L., G. Kuo, A. J. Weiner, L. R. Overby, D. W. Bradley, and M. Houghton. 1989. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 244: 359-362.   DOI